Kelsee, you were clairvoyant in your prediction of a news release during Calgary Stampede.....and it was Hepalink/Taiwain related too! Nice work.

Hopefully Resverlogix isn't as quiet as they were last summer. They had six news releases in the June to August 2016 period last summer.

One announced a webcast presentation at BIO International in June 2016. But no webcast at BIO 2017. Only repetitive slides from investor conferences with very little new info have been shared in 2017.

One announced a Q2 Corporate Update webcast in June 2016. But no update/webcast in Q2 2017, and no update webcast since December 2016.

One announced the start of dosing in the Phase 1 Renal Trial in New Zealand. We are still waiting for news on start of enrollment dosing in the US Phase 1 Renal trial. Long overdue. Really curious as the hold up. Funding?

One announced the filing of the 2016 year end disclosure documents at the end of July 2016. We should see something similar later this month. 

One announced the first BETonMACE DSMB report. We just got the fourth one recently, so likley no more DSMB news until futility analaysis that could occur anytime.

One announced the upcoming 2016 ESC conference in August. We will likley get a 2017 ESC news release too with this similar info.

It was around this time last year we were getting very impatient and composed our list of questions for management (you can look in the off-topic forum if interested). Here we are, a year later and history seems to be repeating itself. It has been almost 7 months since our last webcast/corporate update. And there are a lot of things we could be updated on including but not limited to:

When will the renal trial start recruiting/enrolling patients? 

IND of second compound? And for what indication(s)?

Fabry's disease or PNH trial launch?

New analysts?

New Publications?

FDA/US involvement in BETonMACE?

Plans for the 7 follow on compounds?

Plans to deal with the Citibank/Eastern loan due in late August? 

New website?

Today's news release was unnecessary. The June 28th news release already stated "This recommendation confirms that apabetalone continues to be safe and well-tolerated and with the addition of clinics in Taiwan and Russia, we remain on track for full enrollment by the fall of 2017" stated Dr. Michael Sweeney, M.D., Senior Vice President of Clinical Development."

I would have preferred hearing that the first patients in the US Phase 1 renal trial had been enrolled/randomized instead of the fluff news release from this morning. We need some real news from management. An update is long overdue. Both here and on the Zenith side.

As Kelsee wrote "... and I guess on the plus side August 28th is only six and a half weeks to wait, if they go the distance... so hunker down as the summer ticks away... I gotta believe they will not make us wait till then before they give us news on the financing or other pending news, but it is only wishful thinking... hope I'm right."

It shouldn't be long until we hear something......I hope.

BearDownAZ